Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Jazz Pharmaceuticals PLC (JAZZ) had Consolidated Net Income/Loss of $192.80M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$1.21B |
|
$192.80M |
|
$116.40M |
|
$1.09B |
|
$960.10M |
|
$248.20M |
|
$-37.20M |
|
$211.00M |
|
$211.00M |
|
$192.90M |
|
$192.80M |
|
|
Consolidated Net Income/Loss |
$192.80M |
$192.90M |
|
$248.20M |
|
$427.30M |
|
63.20M |
|
69.40M |
|
$3.05 |
|
$2.78 |
|
| Balance Sheet Financials | |
$3.97B |
|
$212.00M |
|
$7.11B |
|
$11.08B |
|
$2.23B |
|
$3.33B |
|
$4.05B |
|
$6.28B |
|
$4.80B |
|
$-1.03B |
|
$4.80B |
|
64.80M |
|
| Cash Flow Statement Financials | |
$823.90M |
|
$478.00M |
|
$-1.07B |
|
$1.39B |
|
$1.62B |
|
$227.90M |
|
$147.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.78 |
|
-- |
|
-- |
|
0.41 |
|
0.91 |
|
90.37% |
|
20.54% |
|
20.54% |
|
-- |
|
17.46% |
|
15.96% |
|
$786.10M |
|
-- |
|
-- |
|
-- |
|
0.11 |
|
0.26 |
|
1.37 |
|
65.61 |
|
4.02% |
|
-18.76% |
|
1.74% |
|
2.37% |
|
$74.10 |
|
$11.33 |
|
$11.87 |
|